{"hands_on_practices": [{"introduction": "The decision to perform carotid revascularization hinges on an accurate assessment of lesion severity. This practice grounds your skills in the standardized method for quantifying stenosis using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria, a cornerstone of modern vascular surgery. By applying this fundamental calculation, you will connect a key angiographic measurement to the critical determination of clinical indication for intervention, reinforcing the evidence-based principles that guide treatment decisions [@problem_id:5094289].", "problem": "A $68$-year-old patient presents with transient ischemic attacks attributed to a high-grade internal carotid artery lesion. Digital subtraction angiography demonstrates a focal narrowing with a minimal luminal diameter at the point of maximal stenosis $d_{\\text{stenosis}} = 1.8\\,\\text{mm}$ and a normal distal reference internal carotid artery diameter $d_{\\text{distal}} = 5.0\\,\\text{mm}$. Using the definition established by the North American Symptomatic Carotid Endarterectomy Trial (NASCET), compute the fractional diameter stenosis of the lesion as a decimal (not a percentage) and round your answer to four significant figures. Then, based on first principles of vascular hemodynamics and widely accepted clinical thresholds in carotid revascularization, interpret whether this degree of lesion is typically considered for carotid artery stenting (CAS) and whether an embolic protection strategy is indicated, explaining the rationale in terms of stroke risk mitigation. Your final numeric answer must be the computed NASCET fractional diameter stenosis only, expressed as a unitless decimal rounded to four significant figures.", "solution": "The problem statement has been validated and is deemed sound. It is scientifically grounded, well-posed, and objective, providing all necessary information for a complete solution.\n\nThe primary task is to compute the fractional diameter stenosis using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) method and then to interpret the clinical significance of this finding.\n\nFirst, we calculate the stenosis. The NASCET criteria define the degree of stenosis by comparing the minimal luminal diameter at the stenotic site to the diameter of the normal internal carotid artery distal to the stenosis. Let $d_{\\text{stenosis}}$ be the minimal luminal diameter at the point of maximal stenosis and $d_{\\text{distal}}$ be the diameter of the normal distal internal carotid artery. The fractional stenosis, which we will denote as $S_{\\text{NASCET}}$, is given by the formula:\n$$S_{\\text{NASCET}} = \\frac{d_{\\text{distal}} - d_{\\text{stenosis}}}{d_{\\text{distal}}} = 1 - \\frac{d_{\\text{stenosis}}}{d_{\\text{distal}}}$$\nThis value is typically expressed as a percentage by multiplying by $100$, but the problem requests a decimal.\n\nThe given values are:\n- Minimal luminal diameter at stenosis: $d_{\\text{stenosis}} = 1.8\\,\\text{mm}$\n- Normal distal reference diameter: $d_{\\text{distal}} = 5.0\\,\\text{mm}$\n\nSubstituting these values into the formula:\n$$S_{\\text{NASCET}} = 1 - \\frac{1.8}{5.0}$$\n$$S_{\\text{NASCET}} = 1 - 0.36$$\n$$S_{\\text{NASCET}} = 0.64$$\nThe problem requires the answer to be rounded to four significant figures. Thus, the fractional stenosis is $0.6400$. This corresponds to a $64\\%$ diameter stenosis.\n\nNext, we interpret the clinical implications. The patient is symptomatic, presenting with transient ischemic attacks (TIAs). The calculated stenosis is $64\\%$. According to the landmark NASCET trial, surgical revascularization (carotid endarterectomy, CEA) provides a significant benefit in reducing the risk of future stroke for symptomatic patients with carotid stenosis in the range of $70\\%$ to $99\\%$. For symptomatic patients with moderate stenosis, defined as $50\\%$ to $69\\%$, a benefit from revascularization was also demonstrated, albeit of a smaller magnitude than for high-grade stenosis. The patient's $64\\%$ stenosis places them squarely in this category, making them a candidate for carotid revascularization to mitigate the risk of a major stroke.\n\nCarotid Artery Stenting (CAS) has emerged as a less invasive alternative to CEA. Major clinical trials, such as the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), have shown that for symptomatic patients, CAS and CEA have comparable long-term efficacy in preventing stroke. Therefore, for this $68$-year-old symptomatic patient with a $64\\%$ stenosis, CAS is a recognized and appropriate treatment option.\n\nThe final part of the interpretation concerns the use of an embolic protection strategy. The principal mechanism of stroke in patients with carotid artery disease is artery-to-artery embolism, where fragments of the atherosclerotic plaque break off, travel distally, and occlude cerebral vessels. During a CAS procedure, instrumentation of the lesion with wires, balloons, and the stent itself can dislodge plaque material, an event known as iatrogenic embolization. This is a primary cause of periprocedural stroke associated with CAS.\n\nTo mitigate this risk, embolic protection devices (EPDs) are used. These devices are designed to capture embolic debris released during the intervention before it can travel to the brain. The two main types are distal filters, which are placed in the internal carotid artery beyond the lesion to catch debris, and proximal occlusion systems, which temporarily reverse blood flow away from the brain. Given the understood pathophysiology of periprocedural stroke during CAS, the use of an EPD is considered the standard of care. For a patient undergoing CAS for a symptomatic, moderately severe lesion such as this one, an embolic protection strategy is unequivocally indicated to minimize the risk of an iatrogenic stroke.", "answer": "$$\\boxed{0.6400}$$", "id": "5094289"}, {"introduction": "Selecting the appropriately sized carotid stent is a crucial step that balances effective lesion treatment with the minimization of vessel injury and embolic risk. This exercise moves beyond simple diameter matching to incorporate critical biomechanical principles, including arterial compliance, vessel taper, and wall stress limitations [@problem_id:5094290]. By engineering a solution that respects the dynamic properties of the artery, you will develop a deeper appreciation for how first principles of mechanics directly inform optimal device selection and patient safety during carotid artery stenting.", "problem": "A patient with symptomatic high-grade stenosis of the Internal Carotid Artery (ICA) is scheduled for carotid artery stenting under distal Embolic Protection Device (EPD) filtration. In order to reduce the risk of plaque disruption and distal embolization, the stent should match the distal reference lumen at physiologic pressure and avoid excessive oversizing proximally. The distal ICA reference diameter was measured by intravascular ultrasound at a mean arterial pressure of $90 \\, \\text{mmHg}$ and found to be $5.5 \\, \\text{mm}$. The planned post-procedural mean arterial pressure is $105 \\, \\text{mmHg}$. Over the target segment, the vessel exhibits a linear taper from distal to proximal characterized by a gradient of $0.12 \\, \\text{mm}/\\text{cm}$ over a planned stent length of $5 \\, \\text{cm}$. The distal ICA segment compliance (diameter change per pressure change) is $0.004 \\, \\text{mm}/\\text{mmHg}$ around the working pressure range. The vessel wall thickness is $0.7 \\, \\text{mm}$. To mitigate plaque-cap stress and embolic release while the EPD is deployed, you will impose a maximum allowable circumferential wall stress of $85 \\, \\text{kPa}$ under the thin-walled cylinder assumption and uniform mean arterial pressure loading at $105 \\, \\text{mmHg}$. Use $1 \\, \\text{mmHg} = 133.322 \\, \\text{Pa}$.\n\nStarting from first principles, determine the pair of end diameters of a tapered self-expanding stent (distal end and proximal end) that:\n- matches the distal reference lumen adjusted to the planned post-procedural mean arterial pressure by arterial compliance, and\n- respects the taper over the stent length, while\n- not exceeding the maximum allowable circumferential wall stress constraint anywhere along the stent at the planned mean arterial pressure.\n\nRound your final distal and proximal stent end diameters to three significant figures and express them in millimeters. Provide your final answer as a pair in the form $\\left(d_{\\text{distal}}, d_{\\text{proximal}}\\right)$.", "solution": "The problem is subjected to a rigorous validation process to ensure its scientific and logical integrity before a solution is attempted.\n\n### Step 1: Extract Givens\nThe following data and conditions are explicitly provided in the problem statement:\n- Initial mean arterial pressure, $P_{\\text{initial}} = 90 \\, \\text{mmHg}$.\n- Distal Internal Carotid Artery (ICA) reference diameter at $P_{\\text{initial}}$, $d_{\\text{ref, dist}} = 5.5 \\, \\text{mm}$.\n- Planned post-procedural mean arterial pressure, $P_{\\text{final}} = 105 \\, \\text{mmHg}$.\n- Vessel taper gradient, $G = 0.12 \\, \\text{mm}/\\text{cm}$.\n- Planned stent length, $L = 5 \\, \\text{cm}$.\n- Distal ICA compliance, $C = 0.004 \\, \\text{mm}/\\text{mmHg}$.\n- Vessel wall thickness, $t = 0.7 \\, \\text{mm}$.\n- Maximum allowable circumferential wall stress, $\\sigma_{\\theta, \\text{max}} = 85 \\, \\text{kPa}$.\n- Pressure conversion factor, $1 \\, \\text{mmHg} = 133.322 \\, \\text{Pa}$.\n- Modeling assumption: Thin-walled cylinder for stress calculation.\n- Loading assumption: Uniform mean arterial pressure of $P_{\\text{final}}$ along the stented segment.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established criteria:\n- **Scientifically Grounded**: The problem is based on fundamental principles of biomechanics (arterial compliance, Laplace's law for thin-walled cylinders) and established clinical concepts in vascular surgery (carotid stenosis, stenting, embolic protection). All specified values for pressure, diameter, compliance, and material properties are within physiologically plausible ranges. The scenario is a standard, albeit simplified, representation of a real-world clinical engineering problem.\n- **Well-Posed**: The problem is self-contained and provides all necessary quantitative data and constraints to determine a unique solution for the two requested stent diameters. The objectives are clearly stated and do not conflict.\n- **Objective**: The problem is formulated using precise, unbiased language and quantitative metrics. It is free from subjective or opinion-based statements.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid** as it is scientifically grounded, well-posed, and objective. A full, reasoned solution can be constructed.\n\n### Solution Derivation\nThe objective is to determine the distal and proximal diameters of a tapered stent, denoted as $d_{\\text{stent, dist}}$ and $d_{\\text{stent, prox}}$, respectively, that satisfy three conditions: matching the compliant distal vessel diameter, adhering to the vessel taper, and respecting the maximum stress constraint.\n\n**1. Determine the Target Distal Stent Diameter**\nThe stent's distal end must match the distal ICA lumen diameter at the planned post-procedural pressure, $P_{\\text{final}}$. The initial diameter, $d_{\\text{ref, dist}}$, was measured at $P_{\\text{initial}}$. The change in pressure, $\\Delta P$, is:\n$$\n\\Delta P = P_{\\text{final}} - P_{\\text{initial}} = 105 \\, \\text{mmHg} - 90 \\, \\text{mmHg} = 15 \\, \\text{mmHg}\n$$\nThe arterial compliance, $C$, relates the change in diameter to the change in pressure. The resulting increase in diameter, $\\Delta d_{\\text{dist}}$, is:\n$$\n\\Delta d_{\\text{dist}} = C \\times \\Delta P = (0.004 \\, \\frac{\\text{mm}}{\\text{mmHg}}) \\times (15 \\, \\text{mmHg}) = 0.06 \\, \\text{mm}\n$$\nThe target distal stent diameter, $d_{\\text{stent, dist}}$, must match the vessel's diameter at the final pressure. This is the sum of the initial reference diameter and the compliance-induced expansion:\n$$\nd_{\\text{stent, dist}} = d_{\\text{ref, dist}} + \\Delta d_{\\text{dist}} = 5.5 \\, \\text{mm} + 0.06 \\, \\text{mm} = 5.56 \\, \\text{mm}\n$$\n\n**2. Determine the Target Proximal Stent Diameter**\nThe vessel has a linear taper defined by the gradient $G$ over the stent length $L$. The proximal end of the stented segment will have a larger diameter than the distal end. The total increase in diameter over the length $L$ is:\n$$\n\\Delta d_{\\text{taper}} = G \\times L = (0.12 \\, \\frac{\\text{mm}}{\\text{cm}}) \\times (5 \\, \\text{cm}) = 0.6 \\, \\text{mm}\n$$\nThe target proximal stent diameter, $d_{\\text{stent, prox}}$, is the sum of the distal diameter and this taper-induced increase:\n$$\nd_{\\text{stent, prox}} = d_{\\text{stent, dist}} + \\Delta d_{\\text{taper}} = 5.56 \\, \\text{mm} + 0.6 \\, \\text{mm} = 6.16 \\, \\text{mm}\n$$\n\n**3. Verify the Circumferential Wall Stress Constraint**\nThe problem requires that the circumferential wall stress, $\\sigma_{\\theta}$, does not exceed $\\sigma_{\\theta, \\text{max}} = 85 \\, \\text{kPa}$ anywhere along the stent. Under the thin-walled cylinder assumption (Barlow's formula), the circumferential stress is given by:\n$$\n\\sigma_{\\theta} = \\frac{P r}{t}\n$$\nwhere $P$ is the internal pressure, $r$ is the internal radius, and $t$ is the wall thickness. Assuming uniform pressure $P_{\\text{final}}$ and constant wall thickness $t$ along the stented segment, the stress $\\sigma_{\\theta}$ is directly proportional to the radius $r$. Therefore, the maximum stress will occur at the location of the maximum radius, which is at the proximal end of the stent.\n\nWe must calculate $\\sigma_{\\theta, \\text{prox}}$ and ensure it is less than $\\sigma_{\\theta, \\text{max}}$.\nFirst, convert all units to a consistent SI system (meters, Pascals).\nThe pressure $P_{\\text{final}}$ in Pascals is:\n$$\nP_{\\text{final}} = 105 \\, \\text{mmHg} \\times 133.322 \\, \\frac{\\text{Pa}}{\\text{mmHg}} = 13998.81 \\, \\text{Pa}\n$$\nThe maximum radius is the proximal stent radius, $r_{\\text{stent, prox}}$:\n$$\nr_{\\text{stent, prox}} = \\frac{d_{\\text{stent, prox}}}{2} = \\frac{6.16 \\, \\text{mm}}{2} = 3.08 \\, \\text{mm} = 3.08 \\times 10^{-3} \\, \\text{m}\n$$\nThe wall thickness $t$:\n$$\nt = 0.7 \\, \\text{mm} = 0.7 \\times 10^{-3} \\, \\text{m}\n$$\nNow, calculate the maximum circumferential stress at the proximal end:\n$$\n\\sigma_{\\theta, \\text{prox}} = \\frac{P_{\\text{final}} r_{\\text{stent, prox}}}{t} = \\frac{(13998.81 \\, \\text{Pa}) \\times (3.08 \\times 10^{-3} \\, \\text{m})}{0.7 \\times 10^{-3} \\, \\text{m}}\n$$\n$$\n\\sigma_{\\theta, \\text{prox}} = \\frac{13998.81 \\times 3.08}{0.7} \\, \\text{Pa} \\approx 61624.75 \\, \\text{Pa}\n$$\nConverting this stress to kilopascals:\n$$\n\\sigma_{\\theta, \\text{prox}} \\approx 61.6 \\, \\text{kPa}\n$$\nThis calculated maximum stress must be compared to the allowable limit:\n$$\n61.6 \\, \\text{kPa} < 85 \\, \\text{kPa}\n$$\nThe condition is satisfied. The calculated stent diameters are valid.\n\n**4. Final Answer Formulation**\nThe calculated distal and proximal stent diameters are $d_{\\text{stent, dist}} = 5.56 \\, \\text{mm}$ and $d_{\\text{stent, prox}} = 6.16 \\, \\text{mm}$. The problem requires rounding to three significant figures. Both values are already expressed to three significant figures. The final answer is the pair $(d_{\\text{stent, dist}}, d_{\\text{stent, prox}})$.\n\nFinal distal diameter: $5.56 \\, \\text{mm}$.\nFinal proximal diameter: $6.16 \\, \\text{mm}$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n5.56 & 6.16\n\\end{pmatrix}\n}\n$$", "id": "5094290"}, {"introduction": "Advanced clinical practice requires synthesizing multiple streams of data to navigate complex and often non-ideal anatomical scenarios. This capstone problem challenges you to integrate diagnostic findings, patient-specific anatomical constraints, and a nuanced understanding of different embolic protection technologies to formulate a comprehensive revascularization strategy [@problem_id:5094296]. By weighing the relative risks and benefits of various access routes, embolic protection systems, and stent designs, you will practice the high-level clinical reasoning essential for managing challenging cases of carotid artery disease.", "problem": "A $72$-year-old woman presents with recurrent transient monocular vision loss on the right, occurring $3$ times over $2$ weeks, each episode lasting $5$ to $10$ minutes and resolving completely. She underwent right carotid endarterectomy with patch angioplasty $18$ months ago. Duplex ultrasound demonstrates peak systolic velocities consistent with severe restenosis, and computed tomography angiography confirms a concentric, smooth, homogeneously enhancing narrowing beginning at the distal edge of the patch and extending $12 \\text{ mm}$ into the internal carotid artery (ICA). Catheter angiography provides the following measurements: minimal stenotic diameter $D_{\\text{stenosis}} = 1.6 \\text{ mm}$, distal normal ICA diameter $D_{\\text{distal}} = 5.2 \\text{ mm}$, and the length of disease-free straight distal ICA available beyond the stenosis before the petrous bend is $6 \\text{ mm}$. The common carotid artery (CCA) diameter is $8.5 \\text{ mm}$, the external carotid artery (ECA) origin is free of disease, and the aortic arch is type III with significant tortuosity and atheromatous plaque. Neurologic examination is normal. She is taking aspirin and high-intensity statin therapy, with blood pressure well controlled. She has no contralateral carotid occlusion.\n\nUsing fundamental hemodynamic and vascular surgical principles, determine the most appropriate revascularization strategy and embolic protection approach. Consider the following foundational elements:\n\n- The North American Symptomatic Carotid Endarterectomy Trial (NASCET) definition of percent stenosis: $$\\%\\,\\text{stenosis} = \\left(1 - \\frac{D_{\\text{stenosis}}}{D_{\\text{distal}}}\\right)\\times 100\\%.$$\n- For symptomatic carotid stenosis, revascularization provides benefit when stenosis exceeds widely accepted thresholds, and redo carotid endarterectomy entails increased technical risk in a previously operated field, particularly with high-cervical lesions and patch-related geometry.\n- Distal filter-based Embolic Protection Devices (EPD) require passage across the lesion and an adequately long, straight, disease-free distal ICA segment with sufficient diameter to seat the filter; proximal occlusion or flow reversal-based EPD reduce or reverse antegrade flow during lesion crossing.\n- Endovascular stent selection should account for plaque morphology and the need for robust scaffolding across patch edges, balancing deliverability in tortuous anatomy with embolic risk mitigation.\n\nWhich of the following is the best next step?\n\nA. Perform transfemoral carotid artery stenting using a distal filter Embolic Protection Device placed $10$ mm beyond the lesion and deploy a single open-cell stent sized to the distal ICA.\n\nB. Perform transfemoral carotid artery stenting using dual-balloon proximal occlusion Embolic Protection Device (common carotid and external carotid occlusion) with two overlapped open-cell stents to bridge into the high cervical ICA.\n\nC. Perform Transcarotid Artery Revascularization (TCAR) with robust flow reversal Embolic Protection and deploy a single tapered, high-scaffolding micromesh stent that spans from healthy CCA across the patch and into the distal ICA, ensuring coverage of both patch edges and avoiding ECA jailing.\n\nD. Perform redo carotid endarterectomy with patch revision given the concentric nature of the lesion and prior patch angioplasty.\n\nE. Continue best medical therapy alone because restenosis after patch endarterectomy is commonly due to intimal hyperplasia and may be stable.", "solution": "We begin at first principles relevant to decision-making in carotid revascularization.\n\n1. Quantify stenosis using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) definition. From the measurements, $$\\%\\,\\text{stenosis} = \\left(1 - \\frac{D_{\\text{stenosis}}}{D_{\\text{distal}}}\\right)\\times 100\\% = \\left(1 - \\frac{1.6}{5.2}\\right)\\times 100\\% = \\left(1 - 0.3077\\right)\\times 100\\% \\approx 69.23\\%.$$ The patient is symptomatic, so a stenosis of approximately $69\\%$ is clinically significant and meets revascularization thresholds established by robust evidence bases for symptomatic disease.\n\n2. Assess lesion morphology and anatomic constraints. The restenosis is concentric and smooth, consistent with intimal hyperplasia at the patch edge. The available disease-free distal ICA landing zone is $6$ mm before a petrous bend, which is short. Endovascular stents benefit from adequate distal landing zones to seat the distal end away from high curvature; filters typically require an adequately long, straight segment, broadly on the order of $\\approx 20$–$30$ mm in many systems, and a minimum vessel diameter typically $> 3.5$–$4.5$ mm depending on device, to seat securely and avoid wall trauma. The measured distal segment length of $6$ mm is far below such ranges, making distal filter placement impractical and potentially unsafe. Additionally, the aortic arch is type III with significant tortuosity and plaque, increasing catheter manipulation risk during transfemoral access and potentially increasing the baseline embolic risk from arch traversal.\n\n3. Consider embolic protection physics. Under laminar conditions typical of the ICA (Reynolds number generally $< 2000$), particle flux to the brain scales with antegrade velocity, such that embolic particle flux $J$ can be expressed qualitatively as $J \\propto C \\, v$, where $C$ is embolic particle concentration and $v$ is mean antegrade velocity. Proximal occlusion or flow reversal strategies reduce $v$ toward zero or set it negative (reverse), thereby decreasing or reversing embolic transport to the cerebral circulation during lesion crossing and stent deployment. Distal filter protection, while effective in capturing some particles, requires crossing the lesion prior to protection and also is constrained by distal landing requirements not met here.\n\n4. Evaluate reoperation versus endovascular approaches. Redo carotid endarterectomy in a previously operated field involves dissection through scarred planes with increased cranial nerve injury risks and technical hazards, especially for high cervical ICA extension and patch geometry. A concentric, smooth intimal hyperplasia lesion is amenable to stent scaffolding if appropriately protected. Given a type III arch, direct carotid access via Transcarotid Artery Revascularization (TCAR) reduces arch manipulation and utilizes robust flow reversal Embolic Protection, aligning with embolic risk minimization principles.\n\n5. Stent selection logic. Smooth hyperplasia warrants robust scaffolding at the patch edges to prevent edge effect and minimize plaque prolapse. Closed-cell or micromesh stents provide higher scaffolding than open-cell designs. A tapered stent matching CCA–ICA diameter transitions (e.g., proximal $8$–$9$ mm to distal $5$–$6$ mm) reduces oversizing-related trauma and optimizes apposition. A single appropriately sized stent spanning both patch edges is preferable to overlapping stents, which add junctional fracture and flow disturbance risks.\n\nOption-by-option analysis:\n\nA. Transfemoral stenting with distal filter EPD placed $10$ mm beyond the lesion and deployment of an open-cell stent. The distal filter requires an adequately long, straight distal ICA segment. The available segment is $6$ mm, below typical safe ranges (often $\\approx 20$–$30$ mm), and $10$ mm placement beyond the lesion is not feasible given the measured anatomy. Furthermore, the type III arch increases embolic risk with transfemoral access. Open-cell stents provide less scaffolding at patch edges and may permit tissue prolapse. Verdict: Incorrect.\n\nB. Transfemoral stenting with proximal dual-balloon occlusion EPD and overlapped open-cell stents into high cervical ICA. Proximal occlusion EPD is more suitable than distal filters when the distal landing zone is short, as it avoids the need to cross the lesion unprotected. However, transfemoral access through a type III arch with significant plaque entails increased embolic risk before proximal protection is established, and overlapping open-cell stents are suboptimal given the need for high scaffolding and the risks associated with stent overlap (junctional rigidity, altered hemodynamics). While technically possible, this strategy is inferior to an approach that avoids arch traversal and offers robust reversal. Verdict: Incorrect.\n\nC. TCAR with flow reversal EPD and a single tapered, high-scaffolding micromesh stent spanning from healthy CCA across the patch into distal ICA, avoiding ECA jailing. TCAR avoids the tortuous arch, establishes robust flow reversal protection before lesion crossing, and allows precise stent placement. A tapered micromesh stent provides enhanced scaffolding to address patch-edge intimal hyperplasia while accommodating diameter transitions, and a single stent spanning the lesion and both patch edges reduces junctional issues. With $6$ mm distal straight segment, careful landing just proximal to the petrous bend with robust apposition is feasible via direct carotid access. Avoiding ECA jailing preserves ECA flow. This best aligns with fundamental embolic protection and anatomic constraints. Verdict: Correct.\n\nD. Redo carotid endarterectomy with patch revision. Although redo surgery is sometimes indicated, the high-cervical extension, prior patch, and scarred field increase cranial nerve injury and technical risks. For a symptomatic patient with severe restenosis and challenging distal landing, endovascular therapy with robust protection that avoids arch traversal is preferable. Verdict: Incorrect.\n\nE. Best medical therapy alone. The patient is symptomatic ($69\\%$ NASCET stenosis) and has recurrent transient ischemic symptoms; medical therapy alone would not address the elevated near-term stroke risk demonstrated in symptomatic severe carotid stenosis. Verdict: Incorrect.\n\nTherefore, the most appropriate choice is TCAR with flow reversal and a single tapered, high-scaffolding micromesh stent that spans and covers the patch edges while avoiding ECA compromise.", "answer": "$$\\boxed{C}$$", "id": "5094296"}]}